Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin resistance and progressively reduced insulin secretion, which leads to impaired glucose utilization, dyslipidemia and hyperinsulinemia and progressive pancreatic beta cell dysfunction. The incidence of type 2 diabet...

Full description

Bibliographic Details
Main Authors:	Yulia A. Nasykhova, Ziravard N. Tonyan, Anastasiia A. Mikhailova, Maria M. Danilova, Andrey S. Glotov
Format:	Article
Language:	English
Published:	MDPI AG 2020-09-01
Series:	International Journal of Molecular Sciences
Subjects:	type 2 diabetes metformin sulfonylureas meglitinides DPP-4 inhibitors GLP1R agonists
Online Access:	https://www.mdpi.com/1422-0067/21/18/6842

Similar Items

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
by: Chun-Ting Yang, et al.
Published: (2020-06-01)

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
by: Derek Ge, et al.
Published: (2022-12-01)

Inflammation and Incretins
by: Amitabh Hatwal
Published: (2012-01-01)

A Woman With HNF1A-Associated Monogenic Diabetes Treated Successfully With Repaglinide Monotherapy
by: Katherine Cuan, DO, et al.
Published: (2024-03-01)

Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
by: Yi-lin Huang, et al.
Published: (2023-06-01)

Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
by: Hideki Kitaura, et al.
Published: (2021-06-01)

Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
by: Chia-Jen Tsai, et al.
Published: (2022-11-01)

Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
by: Chengcong Chen, et al.
Published: (2019-12-01)

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
by: Badrud Duza Mohammad, et al.
Published: (2022-09-01)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
by: Giuseppe Roberto, et al.
Published: (2022-05-01)

Erectile Dysfunction and Low Sex Drive in Men with Type 2 DM: The Potential Role of Diabetic Pharmacotherapy
by: Hayder M. Al-Kuraishy, et al.
Published: (2016-12-01)

An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
by: Dora Bianka Balogh, et al.
Published: (2023-04-01)

The Anti-Inflammatory Effect of Novel Antidiabetic Agents
by: Panagiotis Theofilis, et al.
Published: (2022-11-01)

SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
by: Awadhesh K Singh, et al.
Published: (2019-01-01)

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
by: Sanbao Chai, et al.
Published: (2022-07-01)

Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
by: Da-Peng Zhang, et al.
Published: (2020-01-01)

Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiaocui Qin, et al.
Published: (2021-07-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)

Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
by: Lili Liu, et al.
Published: (2019-03-01)

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
by: Ghadeer K. Dawwas, et al.
Published: (2018-07-01)

Emerging role of antidiabetic drugs in cardiorenal protection
by: Wen-Jia Fu, et al.
Published: (2024-02-01)

Cardiovascular outcomes of antidiabetic drugs
by: Ranjit Kumar Nath, et al.
Published: (2021-03-01)

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease
by: Federico Bernardini, et al.
Published: (2023-07-01)

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
by: Iuliia G. Samoilova, et al.
Published: (2024-01-01)

NEW APPROACHES IN THE TREATMENT OF TYPE 2 DIABETES - TRANSITION FROM GLUCOSE-CENTRED TO PATIENT-CENTRED MODEL
by: Antoaneta Tsvetkova, et al.
Published: (2021-08-01)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
by: Schernthaner G, et al.
Published: (2017-12-01)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
by: Honghong Zou, et al.
Published: (2017-05-01)

Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety
by: Abdallah M. Beano, et al.
Published: (2017-06-01)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
by: Dario Giugliano, et al.
Published: (2022-03-01)

A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus
by: Biswanath Sharma Sarkar, et al.
Published: (2019-02-01)

A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System
by: Mingrui Li, et al.
Published: (2022-01-01)

Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota
by: Ni Yinhua, et al.
Published: (2022-10-01)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
by: Kunika Saini, et al.
Published: (2023-05-01)

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds
by: Wilke T, et al.
Published: (2022-05-01)

Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
by: Elena-Daniela Grigorescu, et al.
Published: (2023-08-01)

Evaluation of Hypoglycaemic Effects of Dipeptidyl Peptidase–4 Inhibitors and Biguanide on Type-2 Diabetic subjects: A six months trial
by: Naghma Ms., et al.
Published: (2020-12-01)

Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research
by: Xiaoyan Yang, et al.
Published: (2022-03-01)

Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
by: Yaochen Xie, et al.
Published: (2023-06-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)